icelles play a pivotal role in drug delivery [1] [2] [3] [4] . They are small sub-50 nm entities physically assembled by water-soluble amphiphilic surfactants, and can solubilize hydrophobic drug molecules that are not well dissolved in water. Compared with other drug-stabilizing and -delivery strategies (ranging from liposomes, polymer-or protein-drug conjugates and polymeric nanospheres to cells or pathogens) [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , micelles have been received as the first-line technology 3 . Their molecular structures and assembling behaviours are well defined, and a drug solution stabilized by micelles can be easily manufactured. This enables large-scale production and stable clinical performance of the formulations. However, the main challenge with micelles is that all conventional micelles, unless chemically cross-linked [1] [2] [3] 23 , disassemble into free surfactants under diluted conditions (for example, below the critical micelle concentration (CMC), which is typical when infusing the micelle/drug formulation into the body). The drug previously stabilized in the hydrophobic region of a micelle core becomes insoluble due to the loss of micelle structures. This severely reduces its bioavailability and deteriorates its therapeutic performance 3, 24, 25 . This challenge has remained insurmountable since all micelles have an apparent CMC and cannot keep stabilizing a hydrophobic cargo when diluted at the concentration below the CMC 4 . Here, we report that this stability challenge can be potentially solved by a so-called 'sharp polarity contrast' micelle system (Fig. 1) . In this sharp-contrast system, each micelle molecule comprises a superhydrophilic zwitterionic polymer domain and a superhydrophobic lipid domain. The polarity contrast between the two domains is drastically 'sharper'; than in most conventional micelle molecules. We found that sharp-contrast micelles with an appropriate molecular weight (MW) of the zwitterionic polymer have an undetectable ultralow CMC below 2.7 × 10 −6 mM. Such an ultralow CMC for micelles is exceedingly rare, and is at least six orders of magnitude lower than for sodium dodecyl sulphate (SDS; CMC = 8.2 mM; commonly found in cleaning and hygiene products) and four orders of magnitude lower than polysorbate 80 (CMC = 0.012 mM; widely used to formulate drugs; for example, the chemo drug docetaxel under the trade name Taxotere [26] [27] [28] ). The mechanism of using zwitterionic moieties to increase micelle stability appears to be universal and very powerful. When a zwitterionic moiety or polymer was added to a micelle solution (not chemically modifying the micelle), the existing micelle molecules in the new solution were stabilized even at a concentration below its inherent CMC. We demonstrated that the ultralow-CMC micelle can remarkably stabilize hydrophobic cargoes (without micelle dissociation) in extremely diluted conditions, including a clinically relevant dilution condition in serum, while conventional micelles failed. To prove the promising use of ultralow-CMC micelles as next-generation carriers, we prepared a simple docetaxel formulation stabilized by the ultralow-CMC micelle, and intravenously injected it into mice inoculated with melanoma tumour cells (B16F10). This formulation performed significantly better than Taxotere and was able to fully eradicate the tumour. It is worth mentioning that the complete elimination of melanomas solely by chemotherapy has rarely been reported [29] [30] [31] [32] [33] [34] . We attributed the boosted antitumour performance of the old drug to the unprecedented stabilization ability of the ultralow-CMC micelles. We expect that ultralow-CMC micelles can be broadly applied to improve the delivery and outcome of other drugs of high therapeutic value.
. Here, we report that this stability challenge can be potentially solved by a so-called 'sharp polarity contrast' micelle system (Fig. 1) . In this sharp-contrast system, each micelle molecule comprises a superhydrophilic zwitterionic polymer domain and a superhydrophobic lipid domain. The polarity contrast between the two domains is drastically 'sharper'; than in most conventional micelle molecules. We found that sharp-contrast micelles with an appropriate molecular weight (MW) of the zwitterionic polymer have an undetectable ultralow CMC below 2.7 × 10 −6 mM. Such an ultralow CMC for micelles is exceedingly rare, and is at least six orders of magnitude lower than for sodium dodecyl sulphate (SDS; CMC = 8.2 mM; commonly found in cleaning and hygiene products) and four orders of magnitude lower than polysorbate 80 (CMC = 0.012 mM; widely used to formulate drugs; for example, the chemo drug docetaxel under the trade name Taxotere [26] [27] [28] ). The mechanism of using zwitterionic moieties to increase micelle stability appears to be universal and very powerful. When a zwitterionic moiety or polymer was added to a micelle solution (not chemically modifying the micelle), the existing micelle molecules in the new solution were stabilized even at a concentration below its inherent CMC. We demonstrated that the ultralow-CMC micelle can remarkably stabilize hydrophobic cargoes (without micelle dissociation) in extremely diluted conditions, including a clinically relevant dilution condition in serum, while conventional micelles failed. To prove the promising use of ultralow-CMC micelles as next-generation carriers, we prepared a simple docetaxel formulation stabilized by the ultralow-CMC micelle, and intravenously injected it into mice inoculated with melanoma tumour cells (B16F10). This formulation performed significantly better than Taxotere and was able to fully eradicate the tumour. It is worth mentioning that the complete elimination of melanomas solely by chemotherapy has rarely been reported [29] [30] [31] [32] [33] [34] . We attributed the boosted antitumour performance of the old drug to the unprecedented stabilization ability of the ultralow-CMC micelles. We expect that ultralow-CMC micelles can be broadly applied to improve the delivery and outcome of other drugs of high therapeutic value.
Micelle-forming DSPE-PCB 5K. Sharp-contrast micelle-forming molecules-DSPE-PCB 5K (a zwitterionic carboxybetaine polymer (PCB) of 5,000 Da MW conjugated to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) lipid)-were synthesized following our previous method 35 . Their structure is shown in Fig. 1 . DSPE-PCB 5K powder is extremely water soluble, and its resulting micelles were imaged by transmission electron microscopy (TEM) (Fig. 2a) . The size of these micelles was measured by dynamic light scattering (DLS) (Fig. 2b) , which determined the hydrodynamic diameter to be 20 ± 3.5 nm (mean ± standard deviation (s.d.), n = 3) in phosphate buffered saline (PBS). The hydrophobic core domain of the DSPE-PCB 5K micelles was detected using pyrene, as reflected by the decrease in the intensity ratio of the first-to third-highest energy bands (I 1 /I 3 ) in the emission spectra of pyrene from 1.7 in water to 1.1 in micelle solution ( Supplementary Fig. 1 ), following our previous method 36 . It should be noted that PCBs of 5,000 Da MW are extremely water soluble and do not form particles or aggregates (hydrodynamic diameter = 3.7 ± 1.0 nm). The aggregation number (N agg ) of the DSPE-PCB 5K micelles in water was 44 mM-a value that is orders of magnitude lower than the CMCs (>10 −3 mM) of typical micellar systems. We also show that zwitterionic moieties or zwitterionic polymers added to a micelle solution stabilize the micelles at concentrations below their inherent CMC. In a mouse model of melanoma, ultralow-CMC micelles encapsulating docetaxel led to the complete eradication of tumours, whereas conventional docetaxel micellar formulations did not reverse tumour growth. Ultralow-CMC micelles might become next-generation carriers for drug delivery.
. The pyrene method is one of the most sensitive and precise methods of CMC determination [38] [39] [40] . However, it does not have sufficient sensitivity to measure a CMC below 10 −3 mM (ref.
41
) because the final concentration for pyrene is maintained at 6 × 10 −4 mM (in our previous protocol as well as others 36, 42 ) to give good-quality fluorescence spectra. A micelle concentration approaching or below 10 −4 mM cannot significantly change the aggregation behaviour of pyrene, and potential micelle formation cannot be detected (as reflected by a pyrene spectrum change). As a consequence, 1.3 × 10 −3 mM, as measured by the pyrene method, is an upper-CMC estimation for DSPE-PCB 5K. There are other fluorescent dyes, such as 2-p-toluidinylnaphthalene-6-sulphonate and 1-anilinonaphthalene-8-sulphonate [43] [44] [45] , and other ways to determine the CMC, including light and X-ray scattering 46, 47 , surface tension study 48, 49 , and isothermal titration calorimetry 50, 51 . However, none of these can precisely detect a CMC < 10 −4 mM. Limited success in determining a CMC < 10 −4 mM has been achieved by extrapolation of CMC values of structurally similar molecules 52 , and through filtration of radioactively labelled surfactants 53 . However, these approaches are not readily available.
Verification of a new method to determine the CMC. To explore a potential CMC below 10 −3 mM, we developed a 'diluting-concentrating' method. An initial stable colloid was prepared by reducing soluble Au 3+ ions to insoluble gold nanoparticles (NPs) in the presence of micelles at a concentration far above their CMCs. A very small gold NP (< 5 nm) was formed as a non-soluble probe, partitioned into the hydrophobic core of a stabilized micelle. The gold probe size was estimated from the maximum absorbance peak of gold NPs 54 , as well as from the size increase from an empty micelle to a probe-loaded micelle (measured by DLS). The micelle-protected gold NPs were subject to serial dilutions in water and an extremely diluted micelle concentration was reached. Potential aggregation of the gold NPs resulted in an increase in both the hydrodynamic size of the colloid and the maximum absorbance wavelength of the gold NPs 54 , as measured by DLS and ultraviolet spectrometry, respectively. Considering that the samples may have been too diluted for these measurements, they were concentrated using a rotary evaporator at 35 °C under reduced pressure and then re-measured for these parameters. The aggregation of hydrophobic gold NPs cannot be reversed by this concentrating process, and was detected based on their corresponding concentrated samples (Supplementary Text 1). Since cargo aggregation is attributed to the dissociation of protecting micelles, this method indirectly detects CMC values. A series of commercially available common micelles with known CMCs were used to verify this method, including non-ionic micelles (polysorbate 80, DSPE-polyethylene glycol (PEG) 5K and DSPE-PEG 2K), cationic micelles (hexadecyltrimethylammonium bromide (CTAB)), anionic micelles (SDS), zwitterionic carboxybetaine (CB) and sulphobetaine micelles with varied hydrophobic chain lengths (dodecyl dimethylglycine (CB12C), N-tetradecyl-N-N-dimethylglycine (CB14C), 3-(decyldimethylammonio) propane sulphonate (SB10C) and 3-(N,N-dimethylpalmitylammonio)propane sulphonate (SB16C)). Representative measuring curves are shown in Fig. 3 . Measuring curves for all samples tested are shown in Supplementary Fig. 3 . Without exception, the CMC values for all micelles are right-positioned, below which both the hydrodynamic size of the colloid and the maximum absorbance wavelength for gold NPs start to increase significantly (Student's t-test, P < 0.05). Similar to common probes for CMC determination (for example, pyrene, dye molecules and so on), the presence of gold NPs in the hydrophobic micelle core does not seem to influence the dissociation behaviour of micelles. If it did, an artefact signifying that the colloid system does not aggregate below the CMC would appear. DSPE-PCB 5K has an undetectable ultralow CMC. Using the validated diluting-concentrating method, gold NPs protected by DSPE-PCB 5K micelles did not show any signs of cargo aggregation at concentrations as low as 2.7 × 10 −6 mM ( Fig. 3 ; no significant signal increase based on a Student's t-test). Their CMC is considered ultralow and below our current detection limit of 2.7 × 10 −6 mM. The detection limit can potentially be lowered by one order of magnitude by further diluting the micelles (for example, into a 10 l container), then concentrating 1.0-1.5 l each time (using a 2 l evaporation flask). This approach is laboursome and has little room to significantly lower the CMC detection limit. In contrast, DSPE-PEG 5K micelles, which are widely used to construct nanomedicines, had an 
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apparent CMC of about 1 × 10 −3 mM, consistent with the literature values 41, 55, 56 , and dissociated at concentrations at least three orders of magnitude higher than DSPE-PCB 5K. Compared with DSPE-PCB 5K, which has multiple zwitterionic CB moieties as the polar group, CB14C contains only one zwitterionic CB and has a significantly higher CMC at 3.4 × 10 −2 mM. To confirm that DSPE-PCB 5K truly has an ultralow CMC, we performed the following experiments. (1) Gold NP colloid was formed in the presence of PCB 5K, replacing DSPE-PCB 5K, and was found unstable (aggregate). Note that DSPE-PCB 5K/Au colloid was stable at room temperature for weeks without precipitation. This excludes the possibility of PCB tightly interacting with gold NPs, preventing dissociation of DSPE-PCB 5K micelles (an artefact of lowered CMC). (2) The gold NP probe was replaced by a cross-linked polystyrene NP probe. Following the same diluting-concentrating method, where colloid aggregation was detected by DLS, CMC results were obtained similarly to Fig. 3a , regardless of the probe used ( Supplementary Fig. 4 ). It should be noted that both gold and cross-linked polystyrene NPs are non-dissolvable under extremely diluted conditions. This is the key to obtaining reliable CMC results. Dissolvable salt NPs (for example, CaCO 3 ) were not found to work as a probe since they are released from the micelle at a diluted concentration below their water solubility and aggregate when concentrated to a concentration above their water solubility ( Supplementary Fig. 5 ). (3) DSPE-PCB 5K micelles at extremely low concentration (2.7 × 10 −6 mM) were further observed using TEM ( Supplementary Fig. 6 ).
Zwitterionic PCB and its amount are critical to achieving the ultralow-CMC property. To explore the unique role of zwitterionic PCB in contributing to the ultralow-CMC property, we incubated either the free form of the CB moiety or PCB 5K (with multiple CB moieties) at a high concentration with conventional micelles (that is, SDS and polysorbate 80) and found that conventional micelles were significantly stabilized in both cases (Fig. 4a,b and Supplementary  Fig. 7a ,b). It should be noted that a similar stabilizing effect has been found in both inorganic and organic salt solutions 57, 58 . We attribute this effect to the superhydrophilicity of CB and PCB (similar to salts), which increases the polarity of the aqueous phase 35, 59 , strengthens the hydrophobic-hydrophobic interaction and drives the micelle assembly at a concentration far below the micelle's inherent CMC. In contrast, the presence of ethylene glycol oligomer (OEG) or PEG increased the CMC for conventional micelles (Fig. 4a,b and Supplementary Fig. 7a,b) , which is consistent with the literature 60 . OEG and PEG are known for their hydrophobic nature and tend to decrease the polarity of the aqueous environment 35, 59 , behaving in the opposite way to superhydrophilic CB and PCB (Supplementary Text 2). We further examined the micelle stabilizing effects of CB and PCB 5K at a series of concentrations and found that a minimum of roughly 200 mg ml -1 CB and 40 mg ml -1 PCB 5K was required to prevent the dissociation of conventional micelles; for example, SDS and polysorbate 80 ( Supplementary Fig. 7c-f) . Thus, the presence of zwitterionic CB moieties as polar groups for DSPE-PCB 5K appears to be the key to the ultralow-CMC property.
We further found that an appropriate MW of PCB (number of CB moieties per polymer) is critical for DSPE-PCB to achieve the lowest possible CMC (Fig. 4c,d ). The PCB MW needs to be as high as possible to ensure the CMC lowering effect. However, the PCB MW should not be too large since micelles with longer hydrophilic polymer chains typically have an increased CMC (as shown by hydrophilic polyvinylpyrrolidone-hydrophobic alkyl chain micelles 41 ). It appears that DSPE-PCB 5K has a balanced PCB MW and achieves the lowest possible CMC (< 10 −6 mM (undetectable)) compared with DSPE-PCB 2K (CMC = 1.2-6.0 × 10 −5 mM), DSPE-PCB 10K (CMC = 0.9-1.8 × 10 −5 mM) and other reported micelles containing a zwitterionic polymer block 61 .
Ultrastability of ultralow-CMC micelles when diluted in serum.
One major challenge with drug delivery is the dissociation of carrier entities (for example, micelles) as they are infused into the blood stream, since the drug carrier is typically diluted below its CMC. Blood serum comprises a large amount of albumin, which decomposes micelles and binds with these surfactants 62 . Compared with water, dilution in serum is even more challenging for assembled carrier systems. Here, we tested the stability of ultralow CMC and conventional micelles in foetal bovine serum (FBS) using the gold NP probe at a 0.055 mM micelle concentration (Fig. 5) . We found that DSPE-PCB 5K (ultralow CMC) showed excellent stability over 72 h. Conventional polysorbate 80 and DSPE-PEG 5K micelles were not stable; DSPE-PEG 5K micelles dissociated at this concentration even above their CMC. The diluted micelle .
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concentration tested (10 −2 mM) was chosen by considering the situation of a 60 kg adult patient with 4.5 l of blood receiving 75 mg m −2 Taxotere to treat breast cancer 63 . The hypothetical maximum micelle concentration (that is, polysorbate 80) in the blood was calculated to be 5.5 × 10 −2 mM, assuming all of the drug was injected simultaneously. The reality is that Taxotere has to be mixed with infusion saline and slowly infused (typically complete in one hour) 64 . As drugs gradually enter the blood, they are immediately diluted, with the micelle concentration significantly lower than 10 −2 mM. Our serum stability test at 10 −2 mM indicates that ultralow-CMC micelles are far more stable than conventional micelles as drug carriers at clinic-relevant concentrations.
Drastically increased antitumour performance of docetaxel stabilized by ultralow-CMC micelles. To study the applicability of using ultralow-CMC micelles to deliver real drugs, we prepared a docetaxel/DSPE-PCB 5K formulation using a simple thin-film hydration method (see Methods) [65] [66] [67] [68] . Our controls included docetaxel/polysorbate 80 and docetaxel/DSPE-PEG 5K (similarly made using the thin-film hydration method), and Taxotere, formulated based on the literature 63, 64, 28 . The weight ratios of the drug over the surfactant for all formulations were kept at 4%, which is the drug loading level for Taxotere 66, 68 .
The hydrodynamic diameters for all tested samples were around 22 nm, as determined by DLS. However, after diluting these samples in FBS to reach a micelle concentration of 5.5 × 10 −2 mM (the hypothetical maximum micelle concentration in the blood), only docetaxel/DSPE-PCB 5K could maintain its , and upon water dilution, their aggregation behaviour (due to micelle dissociation) was measured by the increase in the maximum absorbance peak of gold (mean ± s.d., n = 3). When 500 mg ml -1 CB was used as the dilution solvent, no significant gold aggregation was observed in the dilution range, indicating a significantly stabilized micelle (despite a concentration below its inherent CMC). In contrast, when 500 mg ml -1 OEG was used as the dilution solvent, gold NP aggregation was observed at high micelle concentrations, showing an increase in the micelle CMC. CB and OEG alone (without the aid of micelles) cannot stabilize gold NPs, leading to severe aggregation. It should be noted that DLS data are not reliable in this experiment since the large concentration of small-sized CB or OEG moieties interferes with the hydrodynamic size readings for aggregated gold NPs. c,d, Diluting-concentrating method to probe CMCs for DSPE-PCB 2K, 5K and 10K micelles. Aggregation of the gold probe at different micelle concentrations was reflected by the gold maximum absorbance wavelength (c) (mean ± s.d., n = 3) and hydrodynamic size of the colloid (d) (mean ± s.d., n = 3). CMC values determined for DSPE-PCB 2K and 10K are indicated by dashed arrows. 
hydrodynamic size, while all other control formulations appeared to be unstable over the tested time period (Fig. 6a) . Drug release profiles were determined by placing the formulations into Slide-ALyzer MINI Dialysis microtubes (3,500 Da MW cut-off) and dialysed against PBS at 37 °C with gentle stirring. Docetaxel remained inside the dialysis tubes and, at different time points, was quantified using high-performance liquid chromatography (HPLC) to calculate the drug release. DSPE-PCB 5K showed the highest retention of docetaxel compared with the other control micelles, with 50% of the drug released in 3.7 h (Supplementary Fig. 8 ). The drug release mechanism in our formulation is expected to be based on drug dissolution or drug leaching. This was indicated by our control study showing that zwitterionic micelles can stabilize non-dissolvable gold NPs and cross-linked polystyrene NPs (Fig. 5 and Supplementary  Fig. 4 ), but not dissolvable CaCO 3 NPs (Supplementary Fig. 5 ), at diluted concentrations. We further checked the stability of different . On day 10 after treatment (marked by an asterisk), a Mann-Whitney U test indicated that docetaxel/DSPE-PCB 5K delayed the tumour growth greater than the four controls at P = 0.005. c, Survival rate curves of mice treated with the different formulations. d, Probability of cure. In mice bearing invisible tumours < 1 mm 3 in size or mice in which flattened and darkened scar tissue developed, it was considered that the tumour had been completely eradicated. e, Concentration of docetaxel in the blood plasma for different formulations (mean ± s.d., n = 4). f, Biodistribution of different docetaxel formulations 24 h after intravenous injection (mean ± s.d., n = 4). A one-way analysis of variance with Bonferroni multi-comparison showed a significant difference between docetaxel/DSPE-PCB 5K and docetaxel/DSPE-PEG 5K, docetaxel/DSPE-PCB 5K and docetaxel/polysorbate 80, and docetaxel/DSPE-PCB 5K and Taxotere (*P < 0.001; **P < 0.0001; **P < 0.0001).
docetaxel formulations after lyophilization. The results indicated that after lyophilization, docetaxel/DSPE-PCB 5K maintained its original hydrodynamic size, while all control micelle formulations significantly aggregated (Supplementary Fig. 9 ).
The maximum tolerated dose of docetaxel/DSPE-PCB 5K was determined, using healthy C57BL/6 mice, to be 55 mg docetaxel kg -1 body weight, which was significantly higher than the control formulations (docetaxel/DSPE-PEG 5K: 40 mg kg ; Supplementary  Fig. 10 ). To examine the antitumour activity of different docetaxel/ micelle formulations, C57BL/6 mice were inoculated with B16F10 cells in the right flank. On day 8 after inoculation, they received an intravenous injection of one of the drug formulations, followed by 4 more every other day. The dose for all drug/micelle formulations was 10 mg docetaxel kg -1 body weight. Docetaxel/DSPE-PCB 5K showed significantly better antitumour activity compared with all other micellar docetaxel formulations, including Taxotere (Fig. 6b) . All tumours treated with this formulation were eliminated by day 33 after the first treatment, without recurrence over the 70 day observation period after tumour innoculation (Fig. 6c,d) . None of the control formulations based on docetaxel was able to fully inhibit the melanoma tumour. In fact, it is rare for any chemotherapy drug to completely eliminate a melanoma [28] [29] [30] 32, [69] [70] [71] [72] .
To further investigate the in vivo circulation profile of docetaxel/ DSPE-PCB 5K, different docetaxel formulations were injected intravenously into healthy C57/BL6 mice. At different time points, blood samples were collected and the concentration of docetaxel in the plasma was measured using HPLC. It was found that docetaxel/ DSPE-PCB 5K showed significantly longer blood circulation than all other micellar docetaxel formulations (Fig. 6e) . The α and β halflives of docetaxel/DSPE-PCB 5K were calculated to be 0.6 and 5.9 h, respectively, while for Taxotere these values were 4 and 36 min, respectively. To study the biodistribution at various time points, healthy C57/BL6 mice were treated with intravenous injections of different docetaxel formulations after inoculation with B16F10 cells. Significantly higher tumour accumulation of docetaxel/DSPE-PCB 5K was observed 24 h post-injection compared with the control formulations (Fig. 6f) . Such enhanced drug accumulation at the tumour site was observed as early as 2 h after administration ( Supplementary Fig. 11 ). We attributed the remarkable antitumour performance of docetaxel in our formulation to the unprecedented stabilization afforded by the ultralow-CMC micelles.
In summary, ultralow-CMC micelles should be applicable as drug carriers on the basis of their ultrastability when protecting cargo (without dissociation) under extremely diluted conditions, including serum dilution in clinically relevant settings where conventional micelle systems fail. It is reasonable to predict that by replacing conventional micelles with ultralow-CMC micelles, the therapeutic outcome of drug delivery will be significantly promoted. Our data support this claim and show that the docetaxel/ultralow-CMC micelle formulation can completely eliminate melanoma tumours in mice, whereas most known chemotherapies, including Taxotere, are unable to do so. We expect that ultralow-CMC micelles can be used to enhance the delivery and therapeutic effects of other drugs as well.
Methods
Materials. DSPE-PCB 2K, 5K and 10K were synthesized and characterized following the previously established method 35 . The MW of N-hydroxysuccinimide ester (NHS)-PCB was characterized by Waters Breeze 2 System gel permeation chromatography with a Waters 2414 Refractive Index Detector. The mobile phase was PBS at a flow rate of 1 ml min -1 . Polysorbate 80, SDS, CTAB, HAuCl 4 , NaBH 4 , styrene, divinylbenzene and trifluoroethanol were obtained from Sigma-Aldrich. DSPE-PEG 5K was obtained from Laysan Bio. CB12C, CB14C, SB10C and SB16C were obtained from Anatrace Products. Docetaxel was obtained from LC Laboratories. B16F10 cells were obtained from the American Type Culture Collection.
Preparation of gold NPs encapsulated by DSPE-PCB 5K. The CMC for DSPE-PCB 5K was determined using the established pyrene method 36 . During the typical diluting-concentrating procedure for CMC determination, a probe (< 5 nm) was first loaded into the micelle core at a high micelle concentration (> CMC). To load the gold NP probe, micelles and HAuCl 4 were dissolved in 10 ml deionized water and vigorously stirred at room temperature, followed by the dropwise addition of 1 ml NaBH 4 aqueous solution (the micelle:gold:NaBH 4 molar ratio was typically 1:1:6). The solution turned red and stirring was continued for another 5 min. To load the cross-linked polystyrene NP probe, micelles, photo-initiator 2959, styrene and divinylbenzene (at a typical molar ratio of 1:10:1.5:1) were sonicated in deionized water to form nano-emulsion, followed by a 20 min reaction under ultraviolet light. Micelles loaded with either gold NPs or polystyrene NPs were further purified using 10K MW cut-off ultrafiltration to remove the rough materials forming the probes, and a 0.2 μ m filter to remove unexpected large particles. The size of the probes was determined by DLS (Zetasizer Nano ZS; Malvern Instruments) by calculating the size difference between empty micelles and loaded micelles. The size of the gold NP probe was determined by measuring the maximum absorbance wavelength using an ultraviolet-visible spectrometer (Thermo Scientific Multiskan GO). During the diluting-concentrating procedure for CMC determination, the liquid sample was not further treated with filtration. The aggregation number (N agg ) of the DSPE-PCB 5K micelles was calculated from the ratio of the apparent molecular mass of a micelle (measured by static light scattering) and the weight-averaged molecular mass of a single DSPE-PCB 5K chain. The apparent molecular mass of the DSPE-PCB 5K micelle was obtained by measuring a series of samples with different concentrations (ranging from 1. ) using the Zetasizer Nano ZS.
Preparation of the docetaxel/DSPE-PCB 5K formulation. To prepare the docetaxel/DSPE-PCB 5K formulation, 150 mg of DSPE-PCB 5K and 6 mg docetaxel were co-dissolved in 5 ml trifluoroethanol in a round-bottom flask. The solvent was subsequently evaporated by rotary evaporation to obtain a thin film. The film was then kept in a vacuum for 2 h at room temperature to remove the residual trifluoroethanol. After the addition of 3 ml saline and stirring at 800 r.p.m. for 30 min, a clear micelle solution loaded with docetaxel was obtained. Docetaxel/ DSPE-PEG 5K and docetaxel/polysorbate 80 formulations were prepared following the same procedure. Taxotere was prepared as in refs 63, 64, 28 . The weight ratios of drug over surfactant for all formulations were kept at 4%, which is the drug loading level for Taxotere 66, 68 . Drug release profiles were determined by placing 100 μ l of different formulations into Slide-A-Lyzer MINI Dialysis microtubes (3,500 Da MW cut-off) and dialysed against PBS at 37 °C with gentle stirring. At different time intervals, the docetaxel remaining in the dialyser was quantified by HPLC using a Waters Breeze 2 System equipped with a Waters 2998 photodiode array detector at 230 nm and a Waters symmetry C 18 column (4.6 × 7.5 mm). The mobile phase was a mixture of acetonitrile and water (50%:50% volume) at a flow rate of 1 ml min W 2 )/2, where L is the long length and W is the short length of the tumour. Mice were euthanized when their weight loss exceeded 15% or their tumour grew to a volume greater than 1,000 mm 3 . For the maximum tolerated dose study, healthy C57BL/6 mice received one intravenous injection of different docetaxel formulations through the tail vein at doses of 25, 40 and 55 mg kg -1 . Treated mice were subsequently observed each day and checked for mortality, body weight and signs of toxicity. To test the docetaxel concentration in the plasma, healthy C57BL/6 mice (7 weeks old, 20-25 g) were treated with intravenous injection via the tail vein at a dosage of 10 mg kg -1 . At different time intervals, 50 µ l blood samples were collected and transferred to tubes treated with sodium heparin. Docetaxel was extracted from the plasma supernatant using ethyl acetate, and the extracted solution was evaporated under a gentle stream of nitrogen. The extraction residues were reconstituted in the mixture of acetonitrile/water (50%:50% volume). The docetaxel concentration was measured using HPLC as described above.
To test the biodistribution, healthy C57BL/6 mice (7 weeks old, 20-25 g) received a subcutaneous injection of 100 µ l B16F10 cells (5 × 10 6 cells ml -1 ) in the right flank. On day 8 post-inoculation, when tumours became visible, different formulations were administered by intravenous injection via the tail vein. Mice were euthanized at certain time points. Organs such as the liver, heart, kidney, spleen, lung and tumour tissues were collected, thoroughly washed with saline (0.9% NaCl), weighed and stored for further analysis. Organs or tissues were homogenized with Mini-Beadbeater-24 (BioSpec Products) in a mixture Nature Biomedical eNgiNeeriNg of acetonitrile and water (50%:50% volume). The resulting 200 µ l samples of homogenized tissue were mixed with 1 ml ethyl acetate. The samples were extracted on a vortex mixer for 2 min then centrifuged at 4,000 g for 5 min. The organic layer was transferred to a clean tube and evaporated under a gentle stream of nitrogen. The extraction residue was reconstituted in a 1 ml mixture of acetonitrile and water (50%:50% volume). The docetaxel concentration was measured using HPLC.
Statistical analysis. Seven mice were included per treatment group unless otherwise specified. The sample size was selected according to previous reports. All tested mice were included in analyses except those with unforeseen sickness or morbidity. Animal cohorts were randomly selected, but investigators were not blind to the experiments. Most data were normally distributed and similar variance was determined for groups that were compared. Analyses included unpaired two-tailed t-tests and one-way analyses of variance with Bonferroni multiplecomparison correction. For data that did not follow normal distribution, a nonparametric Mann-Whitney U test was used. For all statistical analyses, significance was accepted at the 95% confidence level, and all analyses were two-tailed. 
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The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Describe the software used to analyze the data in this study.
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For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
No restrictions on unique materials.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
No antibodies were used.
Eukaryotic cell lines
a. State the source of each eukaryotic cell line used. B16F10 cells (CRL-6475) were purchased from ATCC.
b. Describe the method of cell line authentication used. Cells were authenticated by the vendor.
c. Report whether the cell lines were tested for mycoplasma contamination.
The cell lines were not tested for mycoplasma contamination. No commonly misidentified cell lines were used.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
Animal experiment was approved by the Institutional Animal Care and Use Committee (IACUC) of Wayne State University, and performed in compliance with the relevant laws and institutional guidelines. Healthy C57BL/6 mice (7 weeks old, 20-25 g) were used for experiments.
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
The study did not involve human research participants.
